tumor treating fields + gemcitabine + nab-paclitaxel

**tumor treating fields + gemcitabine + nab-paclitaxel** is an investigational combination therapy for cancer, most notably metastatic pancreatic cancer. It combines three modalities: - **Tumor treating fields (TTFields):** a noninvasive device-based therapy that delivers alternating electric fields via skin arrays to disrupt cancer cell division and induce selective cancer cell death. TTFields exert multimodal effects including disruption of mitosis (via polar tubulin and spindle formation), DNA damage response impairment, autophagy, inhibition of cell adhesion and migration, and augmentation of adaptive antitumor immunity[1][3][5][7]. - **Gemcitabine:** a nucleoside analog chemotherapeutic that inhibits DNA synthesis by incorporating into DNA during replication and inhibiting ribonucleotide reductase, leading to cell cycle arrest and apoptosis[2][4][6][8]. - **Nab-paclitaxel:** a nanoparticle albumin-bound formulation of paclitaxel that stabilizes microtubules and interferes with mitotic spindle function, thus blocking cell division. The albumin carrier also facilitates tumor targeting[2][4][6][8]. This triple combination offers potential synergistic antitumor activity: TTFields disrupt cell division and sensitize tumors to DNA-damaging agents, while gemcitabine and nab-paclitaxel target DNA replication and microtubule function, respectively. Clinical studies have demonstrated the efficacy and tolerability of gemcitabine + nab-paclitaxel for advanced pancreatic cancer, and TTFields are under active investigation as an add-on to this regimen for improved outcomes[1][2][3][4][5][6][8].

Other names

TTFields + gemcitabine + nab-paclitaxel